Veralipride for hot flushes during gonadotropin-releasing hormone agonist treatment

Paolo Vercellini, Nicoletta Vendola, Alberto Colombo, Cristina Passadore, Laura Trespidi, Pier Giorgio Crosignani

Research output: Contribution to journalArticle

Abstract

Hot flushes are the commonest symptom induced by gonadotropin-releasing hormone agonists (GnRHa). We performed an open observational trial to evaluate the efficacy of veralipride, an antidopaminergic drug, in reducing hot flushes in 25 premenopausal women treated with a GnRHa for endometriosis (8 subjects) or menorrhagia (17 subjects). The patients received goserelin depot for 6 months and veralipride was added for the third month. Hot flushes, severe in all women at 2 months, improved in both frequency and intensity in 92% of the subjects during veralipride administration. The benefit obtained persisted until the end of the GnRHa treatment.

Original languageEnglish
Pages (from-to)102-104
Number of pages3
JournalGynecologic and Obstetric Investigation
Volume34
Issue number2
DOIs
Publication statusPublished - 1992

Fingerprint

veralipride
Gonadotropin-Releasing Hormone
Goserelin
Menorrhagia
Endometriosis
Therapeutics
Pharmaceutical Preparations

Keywords

  • Antidopaminergic drugs
  • Gonadotropin-releasing hormone agonists
  • Hot flushes
  • Veralipride

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Reproductive Medicine

Cite this

Veralipride for hot flushes during gonadotropin-releasing hormone agonist treatment. / Vercellini, Paolo; Vendola, Nicoletta; Colombo, Alberto; Passadore, Cristina; Trespidi, Laura; Crosignani, Pier Giorgio.

In: Gynecologic and Obstetric Investigation, Vol. 34, No. 2, 1992, p. 102-104.

Research output: Contribution to journalArticle

Vercellini, Paolo ; Vendola, Nicoletta ; Colombo, Alberto ; Passadore, Cristina ; Trespidi, Laura ; Crosignani, Pier Giorgio. / Veralipride for hot flushes during gonadotropin-releasing hormone agonist treatment. In: Gynecologic and Obstetric Investigation. 1992 ; Vol. 34, No. 2. pp. 102-104.
@article{dfe3829fa22a44588022567708e4dc84,
title = "Veralipride for hot flushes during gonadotropin-releasing hormone agonist treatment",
abstract = "Hot flushes are the commonest symptom induced by gonadotropin-releasing hormone agonists (GnRHa). We performed an open observational trial to evaluate the efficacy of veralipride, an antidopaminergic drug, in reducing hot flushes in 25 premenopausal women treated with a GnRHa for endometriosis (8 subjects) or menorrhagia (17 subjects). The patients received goserelin depot for 6 months and veralipride was added for the third month. Hot flushes, severe in all women at 2 months, improved in both frequency and intensity in 92{\%} of the subjects during veralipride administration. The benefit obtained persisted until the end of the GnRHa treatment.",
keywords = "Antidopaminergic drugs, Gonadotropin-releasing hormone agonists, Hot flushes, Veralipride",
author = "Paolo Vercellini and Nicoletta Vendola and Alberto Colombo and Cristina Passadore and Laura Trespidi and Crosignani, {Pier Giorgio}",
year = "1992",
doi = "10.1159/000292736",
language = "English",
volume = "34",
pages = "102--104",
journal = "Gynecologic and Obstetric Investigation",
issn = "0378-7346",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Veralipride for hot flushes during gonadotropin-releasing hormone agonist treatment

AU - Vercellini, Paolo

AU - Vendola, Nicoletta

AU - Colombo, Alberto

AU - Passadore, Cristina

AU - Trespidi, Laura

AU - Crosignani, Pier Giorgio

PY - 1992

Y1 - 1992

N2 - Hot flushes are the commonest symptom induced by gonadotropin-releasing hormone agonists (GnRHa). We performed an open observational trial to evaluate the efficacy of veralipride, an antidopaminergic drug, in reducing hot flushes in 25 premenopausal women treated with a GnRHa for endometriosis (8 subjects) or menorrhagia (17 subjects). The patients received goserelin depot for 6 months and veralipride was added for the third month. Hot flushes, severe in all women at 2 months, improved in both frequency and intensity in 92% of the subjects during veralipride administration. The benefit obtained persisted until the end of the GnRHa treatment.

AB - Hot flushes are the commonest symptom induced by gonadotropin-releasing hormone agonists (GnRHa). We performed an open observational trial to evaluate the efficacy of veralipride, an antidopaminergic drug, in reducing hot flushes in 25 premenopausal women treated with a GnRHa for endometriosis (8 subjects) or menorrhagia (17 subjects). The patients received goserelin depot for 6 months and veralipride was added for the third month. Hot flushes, severe in all women at 2 months, improved in both frequency and intensity in 92% of the subjects during veralipride administration. The benefit obtained persisted until the end of the GnRHa treatment.

KW - Antidopaminergic drugs

KW - Gonadotropin-releasing hormone agonists

KW - Hot flushes

KW - Veralipride

UR - http://www.scopus.com/inward/record.url?scp=0026697705&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026697705&partnerID=8YFLogxK

U2 - 10.1159/000292736

DO - 10.1159/000292736

M3 - Article

C2 - 1398260

AN - SCOPUS:0026697705

VL - 34

SP - 102

EP - 104

JO - Gynecologic and Obstetric Investigation

JF - Gynecologic and Obstetric Investigation

SN - 0378-7346

IS - 2

ER -